You are here
Apolipoprotein E and kidney function in older adults.
Monday,2013-04-22 18:02 America/Los_Angeles — eenright
| Title | Apolipoprotein E and kidney function in older adults. |
| Publication Type | Journal Article |
| Year of Publication | 2012 |
| Authors | Seshasai, RKurnik, Katz, R, de Boer, IH, Siscovick, D, Shlipak, MG, Rifkin, DE, Sarnak, MJ |
| Journal | Clin Nephrol |
| Volume | 78 |
| Issue | 3 |
| Pagination | 174-80 |
| Date Published | 2012 Sep |
| ISSN | 0301-0430 |
| Keywords | Aged, Aged, 80 and over, Alleles, Apolipoproteins E, Confidence Intervals, Creatinine, Cross-Sectional Studies, Cystatin C, Disease Progression, European Continental Ancestry Group, Female, Gene Frequency, Genotype, Glomerular Filtration Rate, Humans, Kidney, Male, Odds Ratio, Renal Insufficiency, Chronic, Risk Factors |
| Abstract | <p><b>BACKGROUND: </b>Previous studies suggest that the ε4 and ε2 alleles of apolipoprotein E (APOE) may be associated with decreased and increased risks of CKD, respectively, but there are limited data in older adults. We evaluated the associations of apolipoprotein E alleles with kidney function among older adults in the cardiovascular health study (CHS).</p><p><b>METHODS: </b>Caucasian participants had APOE allelic analysis and serum creatinine and cystatin C measured at baseline (n = 3,844 for cross sectional analysis) and in follow up (n = 3,226 for longitudinal analysis). APOE variation was evaluated as an additive model with number of ε2, ε3 and ε4 alleles. GFR was estimated using the CKD epidemiology equation (eGFRcreat) and the cystatin C demographic equation (eGFRcys). The primary outcome was CKD defined by eGFR < 60 ml/min/1.73 m2. The secondary outcome was rapid progression defined by annual loss of eGFR > 3 ml/min/1.73 m2.</p><p><b>RESULTS: </b>Mean eGFRcreat was 72 ml/min/1.73 m2 (25% CKD). Compared with the ε3 allele, the APOE ε4 allele was associated with reduced risk of CKD by eGFRcreat: unadjusted odds ratio (OR) and 95% confidence interval (CI) 0.79 (0.67 - 0.93) per allele, fully adjusted OR (95% CI) 0.80 (0.68 - 0.96) per allele. Results were consistent using eGFRcys. There was no association of the ε2 allele with CKD or between the apolipoprotein E gene with rapid progression.</p><p><b>CONCLUSIONS: </b>The apolipoprotein ε4 allele was associated with lower odds of CKD in elderly Caucasian individuals. Future research should confirm these findings in other races and explore mechanisms to explain these results.</p> |
| Alternate Journal | Clin. Nephrol. |
| PubMed ID | 22874105 |
| PubMed Central ID | PMC3874583 |
| Grant List | R01-AG-027002 / AG / NIA NIH HHS / United States P30 AG024827 / AG / NIA NIH HHS / United States N01-HC-85085 / HC / NHLBI NIH HHS / United States U01 HL080295 / HL / NHLBI NIH HHS / United States N01-HC-85081 / HC / NHLBI NIH HHS / United States HHSN268200800007C / HL / NHLBI NIH HHS / United States K24DK078204 / DK / NIDDK NIH HHS / United States AG-15928 / AG / NIA NIH HHS / United States P30-AG-024827 / AG / NIA NIH HHS / United States HL-075366 / HL / NHLBI NIH HHS / United States AG-20098 / AG / NIA NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States N01-HC-85086 / HC / NHLBI NIH HHS / United States K24 DK078204 / DK / NIDDK NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States AG-027058 / AG / NIA NIH HHS / United States N01-HC-85082 / HC / NHLBI NIH HHS / United States AG-023269 / AG / NIA NIH HHS / United States N01-HC-35129 / HC / NHLBI NIH HHS / United States N01 HC-55222 / HC / NHLBI NIH HHS / United States HHSN268201200036C / HL / NHLBI NIH HHS / United States N01-HC-85083 / HC / NHLBI NIH HHS / United States N01-HC-75150 / HC / NHLBI NIH HHS / United States N01-HC-85080 / HC / NHLBI NIH HHS / United States N01 HC-15103 / HC / NHLBI NIH HHS / United States N01HC85082 / HL / NHLBI NIH HHS / United States N01HC85083 / HL / NHLBI NIH HHS / United States N01-HC-45133 / HC / NHLBI NIH HHS / United States N01-HC-85079 / HC / NHLBI NIH HHS / United States HL080295 / HL / NHLBI NIH HHS / United States N01-HC-85239 / HC / NHLBI NIH HHS / United States N01HC85079 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States N01HC85080 / HL / NHLBI NIH HHS / United States N01-HC-85084 / HC / NHLBI NIH HHS / United States N01HC85081 / HL / NHLBI NIH HHS / United States |